| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
CX614 targets AMPA receptors, which are ionotropic glutamate receptors important for synaptic transmission and plasticity in the brain. It acts as a positive allosteric modulator, enhancing receptor-mediated signaling without directly functioning as a conventional agonist. It occupies subsite A only and modulates channel deactivation and desensitization.
|
|---|---|
| ln Vitro |
CX614 (100 μM) enhances glutamate apparent affinity and increases glutamate-evoked inward current in HEK293 cells, enhancing the response to 3.5 and 10 mM glutamate substantially [1].
CX614 is a positive allosteric modulator of AMPA receptors. It enhances receptor-mediated signaling without directly functioning as a conventional agonist. By increasing glutamate apparent affinity and enhancing glutamate-evoked inward current, CX614 supports stronger excitatory signaling in experimental systems. It enhances excitatory postsynaptic potentials by blocking and slowing the inactivation of responses to glutamate. |
| ln Vivo |
A positive xenobiotic regulator of AMPA transcription, CX614 (1 or 10 mg/kg, intraperitoneally, twice daily), significantly raised BDNF mRNA in the hippocampus and cortex of P5 mice, confirming the elevation of hippocampal BDNF mRNA levels [2].
CX614 has been studied for its effects on synaptic plasticity and neuronal signaling. It enhances excitatory postsynaptic potentials and evokes excitatory postsynaptic currents in neuronal cultures. It can be used for the research of psychiatric disorders such as depression. |
| Enzyme Assay |
CX614 is evaluated in cell-free receptor binding assays to determine its affinity for AMPA receptors. Radioligand binding displacement assays are performed using membrane preparations expressing AMPA receptor subunits. Competition binding experiments are conducted with increasing concentrations of CX614 and a fixed concentration of a labeled reference ligand.
|
| Cell Assay |
CX614 is assessed in cell-based electrophysiological assays using neurons or cells expressing AMPA receptors. The compound's ability to modulate AMPA receptor activity is measured by assessing its effects on excitatory postsynaptic currents and receptor kinetics. It enhances excitatory postsynaptic potentials by blocking and slowing the inactivation of responses to glutamate.
|
| Animal Protocol |
CX614 is administered in animal models to evaluate its effects on synaptic plasticity and behavior. It has been studied in models of depression and other psychiatric disorders. Efficacy is assessed using behavioral tests and electrophysiological recordings.
|
| ADME/Pharmacokinetics |
CX614 has a molecular weight of 247.25 and a molecular formula of C13H13NO4. It has a CAS number of 191744-13-5. The compound is soluble in DMSO (24.73 mg/mL) and ethanol (12.36 mg/mL). It should be stored at +4°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CX614. The compound is for research use only and is not intended for human therapeutic use. Its safety profile has not been extensively characterized in the available literature.
|
| References |
|
| Additional Infomation |
CX614 is an AMPAkine and a positive allosteric modulator of AMPA receptors. It has a CAS number of 191744-13-5. It is a prototypical benzamide that occupies subsite A only. It is used in research to study AMPA receptor function and psychiatric disorders such as depression. It is not approved for clinical use.
|
| Molecular Formula |
C13H13NO4
|
|---|---|
| Molecular Weight |
247.25
|
| Exact Mass |
247.084
|
| CAS # |
191744-13-5
|
| PubChem CID |
6451148
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.45g/cm3
|
| Boiling Point |
473.8ºC at 760 mmHg
|
| Flash Point |
240.3ºC
|
| Vapour Pressure |
3.82E-09mmHg at 25°C
|
| Index of Refraction |
1.651
|
| LogP |
1.35
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
361
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RQEPVMAYUINZRE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H13NO4/c15-13-8-6-10-11(17-5-4-16-10)7-9(8)18-12-2-1-3-14(12)13/h6-7,12H,1-5H2
|
| Chemical Name |
4,7,11-trioxa-16-azatetracyclo[8.7.0.03,8.012,16]heptadeca-1,3(8),9-trien-17-one
|
| Synonyms |
CX-614; CX 614; CX614
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0445 mL | 20.2224 mL | 40.4449 mL | |
| 5 mM | 0.8089 mL | 4.0445 mL | 8.0890 mL | |
| 10 mM | 0.4044 mL | 2.0222 mL | 4.0445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
